Emerging-stage pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) this morning issued a follow-up statement to the memorandum issued by Attorney General Jeff Sessions on January 4, 2018, concerning marijuana enforcement and the repeal of the Cole Memo. In the update, Veritas noted that the AG’s decision largely relates to the recreational cannabis marketplace, in which individual states have allowed sales over the last 24 months. Conversely, the company notes, it does not affect the medical cannabis marketplace. As such, Veritas intends to build on its commitment to advancing the science of medical cannabis in the U.S. states where it is currently legal. Through majority-owned subsidiary Cannevert Therapeutics Ltd., Veritas will continue to support the growing demand for reliable medical grade cannabis aimed at treating a range of conditions, including pain, nausea, epilepsy and PTSD. The company will also continue to actively engage with advisors at both the state and federal levels to provide assistance to government officials regarding the policymaking initiatives currently shaping the medical cannabis market across the United States.
To view the full press release, visit http://cnw.fm/Vc9Vz
About Veritas Pharma Inc.
Veritas Pharma Inc. is an emerging-stage pharmaceutical and IP development company, who, through its 80% owned Cannevert Therapeutics Ltd. (“CTL”), is advancing the science behind medical cannabis. It is the Company aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTL’s unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas investment in CTL is led by strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company’s commercial mission is to patent protect CTL’s IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollar global markets. For more information, visit the company’s website at www.veritaspharmainc.com
More from CannabisNewsBreaks
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.CannabisNewsWire.com